2361 (2361) Fair Value & Analysis

Healthcare · Market cap HK$2.0B

2 2361 2361 · HK

PriceHK$5.00

Fair ValueHK$4.82

Upside-3.6%

Quality68/100

Watch 2361 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$3.16 – HK$6.36

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +0.8% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$2.42 – HK$5.51 · fair‑value band HK$3.16 – HK$6.36 · the HK$5.00 price screens above the HK$4.82 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2361 (2361) currently trades at HK$5.00, while our model-based Fair Value estimate is HK$4.82 — implying the stock looks roughly 3.6% overvalued today. We read business quality at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 2361 generated revenue of HK$419M at a net margin of 22.3%. Revenue grew 11.0% year over year. It earns a return on equity of 12.9%. The stock trades on a trailing P/E of 20.8. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$419M

Revenue growth (YoY) +11.0%

Net margin 22.3%

Return on equity 12.9%

Free cash flow HK$66.4M FY2025

P/E ratio 20.8

More key figures

Operating margin 27.8%

EPS (TTM) HK$0.0600

Dividend yield 1.3%

EPS growth (YoY) -19.0%

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2361 reported revenue of HK$419M in FY2025 versus HK$324M in FY2021, a compound +6.6%/yr. Reported net income was HK$93.4M in FY2025, compounding +4.3%/yr from FY2021.

Revenue +6.6%/yr

FY21 HK$324M

FY22 HK$357M

FY23 HK$396M

FY24 HK$404M

FY25 HK$419M

Net income +4.3%/yr

FY21 HK$78.8M

FY22 HK$55.8M

FY23 HK$102M

FY24 HK$111M

FY25 HK$93.4M

Is 2361 fairly valued? → Check now

Similar stocks

6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Veeva Systems Inc VEEV	$163.76	$103.58	-37%
Pro Medicus Limited PME	A$172.80	A$32.25	-81%
BrightSpring Health Services, Inc BTSG	$57.40	$23.87	-58%
Tempus AI, Inc TEM	$48.61	$12.67	-74%
HealthEquity, Inc HQY	$84.61	$79.57	-6%
M3, Inc MTHRY	$5.03	$7.44	+48%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2361 (2361) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$4.82 versus a price of HK$5.00 — about −4% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2361?

Our model-based fair value for 2361 is HK$4.82 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$5.00.

What is the quality score of 2361?

2361 has a Quality Score of 68/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2361 (2361)?

2361 reported trailing-twelve-month revenue of about HK$419M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2361?

The net profit margin of 2361 is about 22.3%, meaning it keeps roughly 22.3% of revenue as net income. Based on the latest reported figures.

Does 2361 pay a dividend?

2361 currently shows a dividend yield of about 1.27% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.